
Disruptive Trends in Drug and Device Development, with Kymanox President Evan Edwards
Episode 29
In this episode of Life Science Solutions, Evan Edwards, President of Kymanox, explores the key trends shaping the life sciences industry in 2025. From groundbreaking advancements in cell and gene therapies to the rise of GLP-1 drugs and the essential scaling of CDMO operations, Evan highlights the innovations driving product development and commercialization. Key Takeaways: Kymanox Growth: The company is expanding its capabilities, workforce, and global footprint, now employing nearly 300 people across the U.S. and Europe. Industry Trends: Cell and Gene Therapy: Emerging targeted treatments are transforming patient outcomes and delivery methods, including potential home-based solutions. GLP-1 Drugs: These revolutionary therapies are disrupting healthcare and driving rapid market growth. Manufacturing Challenges: A rising need for capacity to meet demand for both innovative and traditional therapies. Artificial Intelligence: Kymanox is leveraging AI responsibly to enhance drug discovery, manufacturing, and regulatory processes. Strategic Focus for 2025: Doubling down on core services like product development, engineering, and regulatory strategy. Expanding into strategic services like CMC, CQV, and human factors expertise. Supporting clients in reaching critical milestones efficiently, saving time and resources.
Publisher
Life Science Solutions
Link
share.transistor.fm/s/2474413a
Published
January 21, 2025
Duration
22 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Kymanox
Life Science Solutions
@lifesciencesolutions
#disruptivetrends #devicedevelopment #kymanoxpresidentevan #lifesciences
